Literature DB >> 6122548

Amino acids in hepatic coma.

J E Fischer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6122548     DOI： 10.1007/bf01311701

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  35 in total

1.  EFFECT OF AN INHIBITOR OF GLUTAMINE SYNTHESIS (METHIONINE SULFOXIMINE) ON AMMONIA TOXICITY AND METABOLISM.

Authors:  K S WARREN; S SCHENKER
Journal:  J Lab Clin Med       Date:  1964-09

2.  The plasma amino acids in patients with liver failure.

Authors:  F L IBER; H ROSEN; S M LEVENSON; T C CHALMERS
Journal:  J Lab Clin Med       Date:  1957-09

3.  Brain tryptophan, plasma free tryptophan and distribution of plasma neutral amino acids.

Authors:  J H James; J M Hodgman; J M Funovics; N Yoshimura; J E Fischer
Journal:  Metabolism       Date:  1976-04       Impact factor: 8.694

4.  Regional brain study of indoleamine metabolism in the rat in acute hepatic failure.

Authors:  M G Cummings; J H James; P B Soeters; J M Keane; J Foster; J E Fischer
Journal:  J Neurochem       Date:  1976-09       Impact factor: 5.372

5.  Insulin, glucagon, portal systemic shunting, and hepatic failure in the dog.

Authors:  P B Soeters; G Weir; A M Ebeid; J E Fischer
Journal:  J Surg Res       Date:  1977-09       Impact factor: 2.192

6.  Can hepatic coma be caused by a reduction of brain noradrenaline or dopamine?

Authors:  L Zieve; R L Olsen
Journal:  Gut       Date:  1977-09       Impact factor: 23.059

7.  Role of a false neurotransmitter, octopamine, in the pathogenesis of hepatic and renal encephalopathy.

Authors:  K C Lam; A R Tall; G B Goldstein; S P Mistilis
Journal:  Scand J Gastroenterol       Date:  1973       Impact factor: 2.423

8.  Synergism between ammonia and fatty acids in the production of coma: implications for hepatic coma.

Authors:  F J Zieve; L Zieve; W M Doizaki; R B Gilsdorf
Journal:  J Pharmacol Exp Ther       Date:  1974-10       Impact factor: 4.030

9.  Treatment of cirrhotic hepatic encephalopathy with L-dopa. A controlled trial.

Authors:  H Michel; M Solere; P Granier; G Cauvet; J P Bali; F Pons; H Bellet-Hermann
Journal:  Gastroenterology       Date:  1980-08       Impact factor: 22.682

10.  Hyperprolactinemia in portal systemic encephalopathy.

Authors:  C J McClain; J P Kromhout; M K Elson; D H Van Thiel
Journal:  Dig Dis Sci       Date:  1981-04       Impact factor: 3.199
View more
  7 in total

Review 1.  Nutritional support in liver disease.

Authors:  D B Silk; S J O'Keefe; C Wicks
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

2.  Plasma amino acids in four models of experimental liver injury in rats.

Authors:  M Holeček; J Mráz; I Tilšer
Journal:  Amino Acids       Date:  1996-09       Impact factor: 3.520

Review 3.  Progress in the treatment of chronic portasystemic encephalopathy.

Authors:  I R Crossley; R Williams
Journal:  Gut       Date:  1984-01       Impact factor: 23.059

Review 4.  Pathophysiology and clinical basis of prevention and treatment of complications of chronic liver disease.

Authors:  S Wagner; H U Lautz; M J Müller; F W Schmidt
Journal:  Klin Wochenschr       Date:  1991-02-06

5.  [Tryptophan metabolism in liver diseases: a pharmacokinetic and enzymatic study].

Authors:  M Rössle; R Herz; B Klein; W Gerok
Journal:  Klin Wochenschr       Date:  1986-07-01

6.  Differentiation between the effects of unprocessed portal blood and reduced liver function on brain indole amine metabolism in the portacaval shunted rat.

Authors:  B Alexander; M Aslam; A Nobin; I S Benjamin
Journal:  Metab Brain Dis       Date:  1998-06       Impact factor: 3.584

7.  A quantitative evaluation of the permeability of the blood brain barrier of portacaval shunted rats.

Authors:  B Alexander; X Li; I S Benjamin; M B Segal; R Sherwood; J E Preston
Journal:  Metab Brain Dis       Date:  2000-06       Impact factor: 3.655
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.